Hfpef clinical trials

Explore recruiting hfpef clinical trials.

Recruiting hfpef studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hfpef trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction

Czechia, Bulgaria, Netherlands, Spain, Poland, Germany +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

C4921003 - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Oral Branched-Chain Ketoacid Dehydrogenase Kinase Inhibitor, PF-07328948 in Adults with Heart Failure (BRANCH-HF)

France, Spain, Bulgaria, Poland, Hungary, Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

Denmark, France, Ireland, Italy, Croatia, Slovenia +18 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)

Germany, Spain, Bulgaria, Poland, Belgium, Latvia +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction

France, Italy, Germany, Czechia, Austria, Poland +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ATHENA: Effects of ziltivekimab versus placebo on heart failure symptoms and physical function in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

Poland, Czechia, Germany, France, Greece, Bulgaria +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hfpef trials by city

Hfpef in Toronto Hfpef in Vancouver Hfpef in Montreal Hfpef in Calgary Hfpef in Edmonton Hfpef in Ottawa Hfpef in Winnipeg Hfpef in Quebec City Hfpef in Hamilton Hfpef in Kitchener Hfpef in London Hfpef in Halifax Hfpef in New York Hfpef in Los Angeles Hfpef in Chicago Hfpef in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease